Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer

NCT07634094 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: Paclitaxel
DRUG: Cisplatin
DRUG: Bioferon
DRUG: Rintatolimod
BIOLOGICAL: αDC1 Vaccine
DRUG: Pembrolizumab
DRUG: Celecoxib
PROCEDURE: Debulking Procedure

Sponsor

Kalinski, Pawel, MD, PhD

Collaborators

[object Object]
[object Object]